MaxCyte’s new clinical and commercial licence agreement with Apeiron Biologics allows the use of MaxCyte’s proprietary Flow Electroporation technology for manufacturing Apeiron’s gene-silencing siRNA therapy, APN401, for clinical studies. The deal is the latest in a series of clinical and commercia
08 Jul 2020
MaxCyte: A win in gene silencing with APEIRON Biologics
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
MaxCyte: A win in gene silencing with APEIRON Biologics
MaxCyte, Inc. (MXCT:LON) | 345 0 0.0% | Mkt Cap: 359.2m
- Published:
08 Jul 2020 -
Author:
Emma Ulker -
Pages:
2
MaxCyte’s new clinical and commercial licence agreement with Apeiron Biologics allows the use of MaxCyte’s proprietary Flow Electroporation technology for manufacturing Apeiron’s gene-silencing siRNA therapy, APN401, for clinical studies. The deal is the latest in a series of clinical and commercia